Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.53USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$2.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,280
52-wk High
$6.06
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $44.88
Shares Outstanding(Mil.): 17.74
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -1.73 -- --
ROI: -69.91 2.89 12.63
ROE: -178.78 1.65 14.82

BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol

* PHASE III CLINICAL STUDY OF THERMODOX IN COMBINATION WITH RADIOFREQUENCY ABLATION TO CONTINUE ACCORDING TO PROTOCOL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 09 2018

Earnings vs. Estimates